ES2172748T3 - Uso de un inhibidor de aldosa reductasa para la reduccion de daño en tejido no cardiaco. - Google Patents

Uso de un inhibidor de aldosa reductasa para la reduccion de daño en tejido no cardiaco.

Info

Publication number
ES2172748T3
ES2172748T3 ES97301172T ES97301172T ES2172748T3 ES 2172748 T3 ES2172748 T3 ES 2172748T3 ES 97301172 T ES97301172 T ES 97301172T ES 97301172 T ES97301172 T ES 97301172T ES 2172748 T3 ES2172748 T3 ES 2172748T3
Authority
ES
Spain
Prior art keywords
cardiac tissue
inhibitor
aldosa
reductasa
reducing damage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97301172T
Other languages
English (en)
Inventor
Thomas A Beyer
Delvin R Knight Jr
Banavara L Mylari
Peter J Oates
Eric R Pettipher
Wayne R Tracey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of ES2172748T3 publication Critical patent/ES2172748T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01021—Aldehyde reductase (1.1.1.21), i.e. aldose-reductase

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

USO DE UN INHIBIDOR DE LA REDUCTASA DE ALDOSA PARA LA FABRICACION DE UN MEDICAMENTO PARA REDUCIR EL DAÑO EN TEJIDO NO CARDIACO DERIVADO DE LA ISQUEMIA EN UN MAMIFERO.
ES97301172T 1996-02-29 1997-02-21 Uso de un inhibidor de aldosa reductasa para la reduccion de daño en tejido no cardiaco. Expired - Lifetime ES2172748T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1270796P 1996-02-29 1996-02-29

Publications (1)

Publication Number Publication Date
ES2172748T3 true ES2172748T3 (es) 2002-10-01

Family

ID=21756300

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97301172T Expired - Lifetime ES2172748T3 (es) 1996-02-29 1997-02-21 Uso de un inhibidor de aldosa reductasa para la reduccion de daño en tejido no cardiaco.

Country Status (14)

Country Link
US (1) US6127367A (es)
EP (1) EP0792643B1 (es)
JP (1) JPH09316003A (es)
KR (1) KR970061252A (es)
CN (1) CN1081460C (es)
AT (1) ATE216239T1 (es)
AU (1) AU724327B2 (es)
CA (1) CA2198564C (es)
DE (1) DE69711972T2 (es)
DK (1) DK0792643T3 (es)
ES (1) ES2172748T3 (es)
IL (1) IL120264A0 (es)
PT (1) PT792643E (es)
ZA (1) ZA971717B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0982306A3 (en) * 1998-08-21 2000-07-05 Pfizer Products Inc. Polymorph of zopolrestat monohydrate
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2002098421A1 (en) * 2001-06-05 2002-12-12 University Of Maryland, Baltimore Novel treatment for neurological and psychiatric disorders
CA2482806A1 (en) 2002-04-30 2003-11-13 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
JP5107053B2 (ja) * 2005-12-16 2012-12-26 株式会社三和化学研究所 急性腎不全の予防または治療剤
WO2007097301A1 (ja) * 2006-02-20 2007-08-30 Sanwa Kagaku Kenkyusho Co., Ltd. 脳卒中における脳虚血又は脳虚血再灌流障害の予防又は治療剤
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
CA2673751C (en) * 2007-01-31 2012-05-08 Sanwa Kagaku Kenkyusho Co., Ltd. Protective agent for retinal nerve or optic nerve
US8273746B2 (en) * 2007-03-23 2012-09-25 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibitors
MX2010002749A (es) 2007-09-14 2010-06-25 Astrazeneca Ab Derivados de ftalazinona.
CA2702429A1 (en) 2007-10-17 2009-04-23 Kudos Pharmaceuticals Limited Crystalline form l 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one
US20110236394A1 (en) * 2007-11-15 2011-09-29 Universite Laval Methods for the regulation of the prostaglandin f synthase (pgfs) activity of akr1b1 and uses thereof
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
EA020783B1 (ru) 2008-10-07 2015-01-30 Астразенека Юк Лимитед Фармацевтическая композиция, содержащая 4-[3-(4-циклопропанкарбонилпиперазин-1-карбонил)-4-фторбензил]-2н-фталазин-1-он и коповидон
EP2654749B1 (en) 2010-12-23 2017-05-10 The Board of Regents of The University of Texas System Methods for treating copd
CN110088384A (zh) 2016-10-19 2019-08-02 品谱公司 用于熨斗的便携式蒸汽发生器基座
GB2619898A (en) 2021-03-18 2023-12-20 Mylari Banavara Combination of aldose reductase inhibitors and probenecid for the treatment of diabetic complications
WO2024053761A1 (ko) * 2022-09-07 2024-03-14 애니머스큐어 주식회사 알도오즈 환원효소 억제제를 포함하는 근원 세포 증식 및 분화 촉진용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4492706A (en) * 1983-08-01 1985-01-08 American Home Products Corporation Method of lowering lipid levels
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
EP0310931A3 (en) * 1987-10-08 1990-10-03 Ethyl Corporation Poultry feed
FR2665440B1 (fr) * 1990-07-31 1994-02-04 Lipha Nouveaux cycloalkylsulfonamides substitues, procedes de preparation et medicaments les contenant.
US5064830A (en) * 1990-08-02 1991-11-12 Pfizer Inc. Lowering of blood uric acid levels
JP3049284B2 (ja) * 1990-11-07 2000-06-05 株式会社三和化学研究所 ヒダントイン誘導体並びにそれを有効成分とする糖尿病合併症及び循環器系疾患の予防及び治療剤
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
US5834466A (en) * 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
CA2208485A1 (en) * 1994-12-22 1996-06-27 Ravichandran Ramasamy Method for protecting the heart from ischemia
IL118474A (en) * 1995-06-01 2001-08-08 Sankyo Co Benzimideol derivatives and pharmaceutical preparations containing them

Also Published As

Publication number Publication date
IL120264A0 (en) 1997-06-10
ZA971717B (en) 1998-08-27
US6127367A (en) 2000-10-03
CA2198564C (en) 2000-06-27
DE69711972D1 (de) 2002-05-23
CN1081460C (zh) 2002-03-27
AU724327B2 (en) 2000-09-14
DE69711972T2 (de) 2002-08-29
CA2198564A1 (en) 1997-08-29
CN1168794A (zh) 1997-12-31
EP0792643B1 (en) 2002-04-17
JPH09316003A (ja) 1997-12-09
DK0792643T3 (da) 2002-07-22
EP0792643A1 (en) 1997-09-03
KR970061252A (ko) 1997-09-12
PT792643E (pt) 2002-08-30
ATE216239T1 (de) 2002-05-15
MX9701533A (es) 1998-06-30
AU1501097A (en) 1997-09-04

Similar Documents

Publication Publication Date Title
ES2172748T3 (es) Uso de un inhibidor de aldosa reductasa para la reduccion de daño en tejido no cardiaco.
DE69717939D1 (de) Am Kopf getragener Projektor
DE59700907D1 (de) Monolithische laserdioden-modulator-kombination
BR9808181B1 (pt) uso de um conservante de madeira e bandagem para a pàs-proteÇço de madeira.
FI935638A (fi) Mobilassisterad handover som anvaender cdma
DE69503640D1 (de) Am kopf montierte anzeigeoptik
BR9707791A (pt) Corpo ótico
AR012673A1 (es) Compuesto de ester de etilenglicol de monohidrobenzoporfirina utiles para terapia fotodinamica, composiciones farmaceuticas y uso de los mismos.
DE69701537D1 (de) Integrierte Laserlichtquelle
DE69736109D1 (de) Differenzierungsinhibitor
DE69836202D1 (de) Katadioptrisches optisches system, optischer kopf, optisches plattenlaufwerk mit dem system sowie optische platte
NO991627L (no) Sekundµr inhibitor for grÕ stµr
DE69700103D1 (de) Quantum Cascade Laser
DE69726053D1 (de) Optischer Kopf
DK0791355T3 (da) Fremgangsmåde til reduktion af vævsbeskadigelse forbundet med iskæmi
ES1042704Y (es) "accesorio para cajon".
ES2175228T3 (es) Metilsulfomicina i, un procedimiento para su produccion y su uso.
DE59708321D1 (de) Innengekühlte Turbomaschinenschaufel
DE69717571D1 (de) Optischer Kopf
ES1027204Y (es) Sonda tutorizada para via lacrimal.
ITMI960764V0 (it) Corpo illuminante per la riflessione di vari fasci luminosi
PT101254A (pt) Trocarter para uso medico-veterinaria
BR7601372U (pt) Disposição construtiva em cuia para chimarrão
ES1028855Y (es) Mecanismo extensible lateral para mesas
KR970060998U (ko) 작업등이 설치된 임팩트

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 792643

Country of ref document: ES